Preliminary Final Report
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The report indicates a significant increase in the operating loss compared to the previous year, attributed to heightened research and development expenditures. The company did not declare any dividends during the financial year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- R327G Highly Effective in Burn Wounds Model
- Recce Signs Debt Facility with Avenue Capital Group
- Successful Placement of Entitlement Offer Shortfall
- China Patent Accepted for RECCE Anti-Infectives
- Recce Enters into USA Department of Defense R&D Agreement
Later from Recce Pharmaceuticals
- Patient Dosing Underway in Ph 3 Indonesia DFI Trial
- Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
- Hong Kong Patent Granted for RECCE Anti-Infectives
- RCE Awarded Advanced Overseas Finding up to A$85m
- AUD $5.3m R&D Rebate Received
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals